Abstract

This paper primarily discusses about the influence of atorvastatin plus aspirin on efficacy and inflammatory factors in patients with cerebral venous thrombosis. The study participants comprised 240 cerebral venous thrombosis patients selected between January 2020 and June 2022 who were grouped as a conventional group (n=107) treated with aspirin and a research group (n=133) treated by atorvastatin+aspirin based on the therapy they received. Statistical and comparative analysis were made regarding the curative efficacy, adverse events (gastrointestinal discomfort, nausea, vomiting and dizziness), inflammatory factors (interleukin-6, tumor necrosis factor-alpha, procalcitonin, high-sensitivity C-reactive protein), platelet parameters (hematocrit, platelet adhesion rate), nerve function injury (National Institute of Health Stroke Scale) and activities of daily living. Based on the analysis results, the research group had a higher overall response rate, a lower complication rate and reduced inflammatory factors, platelet parameters and National Institute of Health Stroke Scale scores than the conventional group, as well as notably higher post-treatment activities of daily living, with statistical significance. From the above, it can be concluded that atorvastatin+aspirin is significantly effective in treating cerebral venous thrombosis, validly inhibiting inflammation, improving platelet parameters, alleviating neurological impairment and enhancing patients’ activities of daily living.